Yuanming Pan

Prof. Yuanming Pan

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2023 in Life Sciences
Verified
Journal Article
Closed access
YFYanxia Fu
Yanxia Fu
CZChen Zhang
Chen Zhang
HXHui Xie
Hui Xie
ZWZisheng Wu
Zisheng Wu
YTYurong Tao
Yurong Tao
YPYuanming Pan
Yuanming Pan

16 April 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
SFShiying Feng
Shiying Feng
HLHuiqin Liu
Huiqin Liu
CYCuilan Yun
Cuilan Yun
WZWei Zhu
Wei Zhu
YPYuanming Pan
Yuanming Pan
Brain tumors, both primary and secondary, represent a significant clinical challenge due to their high mortality and limited treatment options. Primary brain tumors, such as gliomas and meningiomas, and brain metastases from cancers such as non-small cell lung cancer and breast cancer require innovative therapeutic strategies. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR -TKIs) have emerged as a promising treatment option, particularly for tumors harboring EGFR mutations. This review examines the use of EGFR-TKIs in brain tumors, highlighting both laboratory and clinical research findings. In primary brain tumors and brain metastases, EGFR-TKIs have shown potential in controlling tumor growth and improving patient outcomes. Advanced applications, such as nano-formulated EGFR-TKIs and combination therapies with other pathway inhibitors, are being investigated to improve efficacy and overcome resistance. Challenges such as treatment-related events, resistance mechanisms and blood-brain barrier penetration remain significant hurdles. Addressing tumor heterogeneity through personalized medicine approaches is critical to optimizing EGFR-TKI therapies. This review highlights the need for continued research to refine these therapies and improve survival for patients with brain tumors.

4 January 2024 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
JYJianwei Yu
Jianwei Yu
YJYan Jia
Yan Jia
QYQichao Yu
Qichao Yu
LLLan Lin
Lan Lin
CLChao Li
Chao Li
YPYuanming Pan
Yuanming Pan
Introduction: Helicobacter pylori (H.pylori, Hp) affects billions of people worldwide. However, the emerging resistance of Hp to antibiotics challenges the effectiveness of current treatments. Investigating the genotype-phenotype connection for Hp using next-generation sequencing could enhance our understanding of this resistance.Methods: In this study, we analyzed 52 Hp strains collected from various hospitals. The susceptibility of these strains to five antibiotics was assessed using the agar dilution assay. Whole-genome sequencing was then performed to screen the antimicrobial resistance (AMR) genotypes of these Hp strains. To model the relationship between drug resistance and genotype, we employed univariate statistical tests, unsupervised machine learning, and supervised machine learning techniques, including the development of support vector machine models.Results: Our models for predicting Amoxicillin resistance demonstrated 66% sensitivity and 100% specificity, while those for Clarithromycin resistance showed 100% sensitivity and 100% specificity. These results outperformed the known resistance sites for Amoxicillin (A1834G) and Clarithromycin (A2147), which had sensitivities of 22.2% and 87%, and specificities of 100% and 96%, respectively.Discussion: Our study demonstrates that predictive modeling using supervised learning algorithms with feature selection can yield diagnostic models with higher predictive power compared to models relying on single single-nucleotide polymorphism (SNP) sites. This approach significantly contributes to enhancing the precision and effectiveness of antibiotic treatment strategies for Hp infections. The application of whole-genome sequencing for Hp presents a promising pathway for advancing personalized medicine in this context.

5 May 2023 in Frontiers in Oncology
Verified
Journal Article
Open access
DZDongrui Zhang
Dongrui Zhang
BLBaohua Lu
Baohua Lu
BLBowen Liang
Bowen Liang
BLBo Li
Bo Li
ZWZiyu Wang
Ziyu Wang
YPYuanming Pan
Yuanming Pan
Background: Small cell lung cancer (SCLC) is an aggressive and almost universally lethal neoplasm. There is no accurate predictive method for its prognosis. Artificial intelligence deep learning may bring new hope.Methods: By searching the Surveillance, Epidemiology, and End Results database (SEER), 21,093 patients’ clinical data were eventually included. Data were then divided into two groups (train dataset/test dataset). The train dataset (diagnosed in 2010–2014, N = 17,296) was utilized to conduct a deep learning survival model, validated by itself and the test dataset (diagnosed in 2015, N = 3,797) in parallel. According to clinical experience, age, sex, tumor site, T, N, M stage (7th American Joint Committee on Cancer TNM stage), tumor size, surgery, chemotherapy, radiotherapy, and history of malignancy were chosen as predictive clinical features. The C-index was the main indicator to evaluate model performance.Results: The predictive model had a 0.7181 C-index (95% confidence intervals, CIs, 0.7174–0.7187) in the train dataset and a 0.7208 C-index (95% CIs, 0.7202–0.7215) in the test dataset. These indicated that it had a reliable predictive value on OS for SCLC, so it was then packaged as a Windows software which is free for doctors, researchers, and patients to use.Conclusion: The interpretable deep learning survival predictive tool for small cell lung cancer developed by this study had a reliable predictive value on their overall survival. More biomarkers may help improve the prognostic predictive performance of small cell lung cancer.

20 February 2026 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
RWRuijun Wang
Ruijun Wang
ZHZhanbiao He
Zhanbiao He
ZLZhiqi Li
Zhiqi Li
YPYuanming Pan
Yuanming Pan
SBShuang Bai
Shuang Bai
In recent years, the role of gut microbiota in the regulation of the gut-brain axis has garnered increasing attention, with Muribaculum intestinale ( M. intestinale ) emerging as a novel member of the gut microbiota, exhibiting unique biological characteristics and potential therapeutic value. This article systematically reviews the regulatory mechanisms of M. intestinale in the gut-brain axis and its associations with various diseases. M. intestinale modulates host neurotransmitter synthesis, immune responses, and intestinal barrier function through metabolites such as short-chain fatty acids, succinate, and 3-hydroxybutyrate, thereby influencing the progression of neurodegenerative disorders, psychiatric diseases, and metabolic diseases. Additionally, this article explores the distribution differences of M. intestinale in the intestines of mice and humans, as well as its susceptibility to external factors like diet, antibiotics, and exercise. Although current research has unveiled the potential roles of M. intestinale , its clinical translation still faces challenges such as technical bottlenecks and individual variability. Future studies should focus on humanized model construction, synthetic biology modifications, and multi-target intervention strategies to achieve precise microbiota-targeted therapies.

29 August 2024 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
CLChao Li
Chao Li
XYXinxin Yin
Xinxin Yin
CXChangpeng Xie
Changpeng Xie
JZJin Zeng
Jin Zeng
CSChuan Song
Chuan Song
YPYuanming Pan
Yuanming Pan
Objective: To investigate the effects of berberine (BBR) as a treatment on intestinal microecological alterations and enteritis in mice produced by TNBS.Methods: There were seven mice per group: seven in the healthy group (Ctrl), seven in the TNBS-induced enteritis group (TNBS), and seven in the berberine treatment group (BBR). The mice were weighed, slaughtered after 7 days, and subjected to high-throughput intestinal microecological analysis by Illumina, as well as haematological detection and imaging evaluation of colon pathology.Results: The alterations in colon length, immune cell subpopulations, inflammatory factors, and intestinal microecology of mice induced by BBR were refined using a battery of experiments and observations. According to intestinal microecological studies, BBR can increase the number of bacteria, including Lactobacillus, Verrucomicrobia, Bacteroides, and Akkermansia muciniphila.Conclusion: BBR has a therapeutic effect on TNBS-induced colitis in mice, which is associated with modifications in immune cell subpopulations and intestinal microecology. It also offers a viable approach as a prospective probiotic (like Akkermansia muciniphila) to IBD therapy in clinical settings.